

## Result of AGM

Released : May 19, 2020

RNS Number : 3820N  
Diaceutics PLC  
19 May 2020

19 May 2020

**Diaceutics PLC**  
**("Diaceutics" or the "Company")**

**Results of Annual General Meeting**

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.

Details of the proxy votes received on each resolution by Diaceutics' Registrar are set out below:

Resolution	For & Discretionary		Against		Withheld	Total votes cast	
	Number of votes	%	Number of votes	%	Number of votes		
1	Ordinary resolution to receive and consider the 2019 Financial Statements	50,023,247	100.00%	0	0.00%	0	50,023,247
2	Ordinary resolution to re-elect Julie Goonewardene as a director	49,984,878	99.92%	38,369	0.08%	0	50,023,247
3	Ordinary resolution to re-elect Charles Hindson as a director	49,969,009	100.00%	0	0.00%	54,238	49,969,009
4	Ordinary resolution to re-elect Mike Wort as a director	49,969,009	100.00%	0	0.00%	54,238	49,969,009
5	Ordinary resolution to re-elect Peter Keeling as a director	50,023,247	100.00%	0	0.00%	0	50,023,247
6	Ordinary resolution to re-elect Ryan Keeling as a director	49,984,878	99.92%	38,369	0.08%	0	50,023,247
7	Ordinary resolution to re-elect Philip White as a director	50,023,247	100.00%	0	0.00%	0	50,023,247
8	Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors	49,984,878	100.00%	0	0.00%	38,369	49,984,878
9	Ordinary resolution to authorise the directors to determine the remuneration of the auditors	50,007,378	100.00%	0	0.00%	15,869	50,007,378
10	Ordinary resolution to authorise the directors to allot shares	49,984,878	99.92%	38,369	0.08%	0	50,023,247
11	Special resolution to authorise the directors to disapply pre-emption rights	49,983,480	99.92%	39,767	0.08%	0	50,023,247
12	Special resolution to authorise the directors to purchase own shares	47,744,794	99.92%	39,453	0.08%	2,239,000	47,784,247

## Enquiries

### **Diaceutics PLC**

Stuart Hunt, Head of Investor Relations

Tel: +44 (0)7815 778 536

### **Cenkos Securities PLC (Nomad & Broker)**

Callum Davidson / Giles Balleny

Michael Johnson (Sales)

Tel: +44(0)20 7397 8900

### **Walbrook PR**

Anna Dunphy

Paul McManus

Tel: +44 (0)20 7933 8780 or  
diaceutics@walbrookpr.com

Tel: +44 (0)7876 741 001

Tel: +44 (0)7980 541 893

## **About Diaceutics**

Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. [www.diaceutics.com](http://www.diaceutics.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

RAGZZGMKFLN GGZM